Synopsis Bone anabolic agents increase the volume of bone, leading to an increase in measured bone mineral density, by decreasing the remodeling space and increasing the degree of mineralization. A sequential therapy with alendronate (ALN) following Abaloparatide (ABL) was employed in an extension of the phase 2 trial, resulting in prolonged effects on bone mineral density. The present study assesses the long-term safety and efficacy of extended treatment with Alendronate (ALN) following 18 months of Abaloparatide (ABL) or placebo. This week’s “ MED FACT ” discusses a randomized clinical trial from The Journal of Clinical Endocrinology & Metabolism, “ ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis ”. Authors: H.
G. Bone, et. al. Key Takeaways Twenty-four months of Alendronate after 18 months of Abaloparatide or Placebo…
